Yanfei Shao
Overview
Explore the profile of Yanfei Shao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
279
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu X, Shen S, Dong Y, Jiang L, Wang J, Shao Y
Phytomedicine
. 2025 Jan;
138:156385.
PMID: 39823801
Background: Puerarin is a crucial constituent separated from the Chinese herbaceous plant, Pueraria lobata (Willd.) Ohwi, which exhibits multiple biological activities. Previous studies have indicated that puerarin has a function...
2.
Zhou M, Shao Y, Chen W, Guan B, Xie B, Liu Y, et al.
BMC Gastroenterol
. 2024 Dec;
24(1):449.
PMID: 39627699
Background: Maintaining iron homeostasis is crucial for preventing the development of colorectal cancer (CRC). However, Evidence regarding the correlation between serum iron status and CRC has been inconsistent. This population-based...
3.
Shao Y, Yu M, Zhang L, Zhou L, Yan X, Feng B, et al.
Sci Rep
. 2024 Nov;
14(1):28535.
PMID: 39558044
Colorectal cancer (CRC) lymph node metastasis (LNM) is a crucial factor affecting the prognosis and treatment outcomes of CRC patients. It has been confirmed that altered glycosylation is a key...
4.
Zhou X, Lin J, Shao Y, Zheng H, Yang Y, Li S, et al.
Int J Biol Sci
. 2024 Nov;
20(14):5548-5575.
PMID: 39494327
Tumor progression and limited benefits of immune checkpoint blockade (ICB) therapy have been two major challenges in the clinical management of colorectal cancer (CRC). The objective of our research was...
5.
Yang G, Ding C, Yang X, Jiang J, He S, Shao Y, et al.
J Adv Res
. 2024 Aug;
PMID: 39128702
Introduction: Cetuximab (CTX) is an effective targeted drug for the treatment of metastatic colorectal cancer, but it is effective only in patients with wild-type KRAS genes. Even in this subset...
6.
Huang L, Yang G, Shao Y, Sun J, Yang X, Hong H, et al.
Int J Biol Sci
. 2024 May;
20(7):2388-2402.
PMID: 38725844
Metastasis is the leading cause of death in colorectal cancer (CRC) patients. By mediating intercellular communication, exosomes exhibit considerable value in regulating tumor metastasis. Long non-coding RNAs (lncRNAs) are abundant...
7.
Gao R, Yuan X, Ma Y, Wei T, Johnston L, Shao Y, et al.
Cell Rep Med
. 2024 May;
5(5):101536.
PMID: 38697103
Spatial transcriptomics (ST) provides insights into the tumor microenvironment (TME), which is closely associated with cancer prognosis, but ST has limited clinical availability. In this study, we provide a powerful...
8.
Li S, Li Z, Xue K, Zhou X, Ding C, Shao Y, et al.
Int J Med Inform
. 2024 Mar;
185:105402.
PMID: 38467099
Background: Gastric cancer (GC) is one of the most common malignant tumors in the world, posing a serious threat to human health. Currently, gastric cancer treatment strategies emphasize a multidisciplinary...
9.
Cheng M, Shao Y, Li L, Jiang M, Song Z
BMC Cancer
. 2024 Mar;
24(1):312.
PMID: 38448878
Background: There are differences in the pharmacoeconomics of Immune checkpoint blocking (ICB) therapies for the treatment of lung squamous cell carcinoma (LSCC). However, no corresponding review studies have fully discussed...
10.
Shao Y, Yesseyeva G, Zhi Y, Zhou J, Zong J, Zhou X, et al.
Genomics
. 2024 Mar;
116(2):110821.
PMID: 38447684
Prefoldin Subunit 5 (PFDN5) plays a critical role as a member of the prefoldins (PFDNs) in maintaining a finely tuned equilibrium between protein production and degradation. However, there has been...